Syncromune® Inc. Presents Positive Results from SYNC-T™ SV-102 Phase 1 Trial at AACR Annual Meeting 2024
FORT LAUDERDALE, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, an in situ personalized therapy optimized for solid tumor cancers, today announced the presentation of positive results from the SV-102 Phase 1 trial at the American Association for Cancer Research (AACR) Annual Meeting 2024. The trial, involving patients with metastatic castrate-resistant prostate cancer (mCRPC), showed an overall response rate (ORR) of 85%.
- FORT LAUDERDALE, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, an in situ personalized therapy optimized for solid tumor cancers, today announced the presentation of positive results from the SV-102 Phase 1 trial at the American Association for Cancer Research (AACR) Annual Meeting 2024.
- The trial, involving patients with metastatic castrate-resistant prostate cancer (mCRPC), showed an overall response rate (ORR) of 85%.
- The Phase 1 trial enrolled 15 mCRPC subjects, most of whom had diffuse bone metastases and had experienced failure with prior therapies.
- The trial is ongoing, with results expected in the second half of 2024.